Lion TCR
Singapore, Singapore· Est.
Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $40M
AI Company Overview
Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.
OncologyInfectious Diseases
Technology Platform
mRNA‑encoded, virus‑specific TCR‑T cell therapy with transient expression for safe, rapid, personalized immunotherapy against HBV‑related cancers.
Opportunities
Expansion of the mRNA‑TCR platform to other viral‑associated cancers (EBV, CMV) and development of allogeneic off‑the‑shelf products could unlock sizable Asian and global markets.
Risk Factors
Regulatory uncertainty for mRNA‑engineered cell therapies, manufacturing scale‑up challenges, and competition from viral‑vector TCR platforms may affect timelines and market uptake.
Competitive Landscape
Key competitors include Adaptimmune (Gilead), TCR2 Therapeutics, and other mRNA‑based cell therapy firms; Lion TCR differentiates through transient mRNA expression and a large HBV‑specific TCR library covering Asian HLA diversity.